The two speakers will discuss the pro and cons of starting the newly approved biologic dupilumab for management of nasal polyps. The discussion will focus on cost, adherence, quality of life and the role of follow up with patients being treated.

Upon completion of this activity, participants should be able to:

  • Identify when and how to use dupilumab in management of chronic rhinosinusitis with nasal polyps
  • Describe how duplimab works and can prevent surgery 


Moderator Introduction
Mahboobeh Mahdavinia, MD PhD FAAAAI
Rush University Medical Center

Surgery is the Obvious Choice
Robert  C. Kern, MD
Northwestern University

Dupilumab is the Obvious Choice
Anju  T. Peters, MD MSCI FAAAAI
Northwestern University Medical School

Please take a moment to click the link below and give us your feedback on this session: